What is the generic name of the ANGPTL3 inhibitor used for HoFH?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Multiple Choice

What is the generic name of the ANGPTL3 inhibitor used for HoFH?

In HoFH, where LDL receptor function is severely impaired, therapies that lower LDL-C without relying on LDL receptor activity are especially valuable. The ANGPTL3 inhibitor used for HoFH is evinacumab. It is a monoclonal antibody that blocks ANGPTL3, lifting its inhibition of lipoprotein lipase and related pathways. This leads to enhanced breakdown of triglyceride-rich lipoproteins and reduced production of VLDL remnants, which in turn lowers LDL-C even when LDL receptors are not working well. The other drugs listed are not ANGPTL3 inhibitors: alirocumab is a PCSK9 inhibitor; lomitapide inhibits MTTP and reduces VLDL production; ezetimibe blocks intestinal cholesterol absorption.

In HoFH, where LDL receptor function is severely impaired, therapies that lower LDL-C without relying on LDL receptor activity are especially valuable. The ANGPTL3 inhibitor used for HoFH is evinacumab. It is a monoclonal antibody that blocks ANGPTL3, lifting its inhibition of lipoprotein lipase and related pathways. This leads to enhanced breakdown of triglyceride-rich lipoproteins and reduced production of VLDL remnants, which in turn lowers LDL-C even when LDL receptors are not working well. The other drugs listed are not ANGPTL3 inhibitors: alirocumab is a PCSK9 inhibitor; lomitapide inhibits MTTP and reduces VLDL production; ezetimibe blocks intestinal cholesterol absorption.

More practice questions